|
1
|
Wakatsuki K, Matsumoto S, Migita K, Ito M,
Kunishige T, Nakade H, Nakatani M, Kitano M, Takano M, Obayashi C,
et al: Usefulness of computed tomography density of a tumor in
predicting the response of advanced esophageal cancer to
preoperative chemotherapy. Surgery. 162:823–835. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Servagi-Vernat S, Créhange G, Bonnetain F,
Mertens C, Brain E and Bosset JF: Chemoradiation in elderly
esophageal cancer patients: Rationale and design of a phase I/II
multicenter study (OSAGE). BMC Cancer. 17:4832017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Canto MI, Abrams J, Kunzli H, Weusten B,
Komatsu Y, Jobe BA and Lightdale CJ: Nitrous oxide cryotherapy for
treatment of esophageal squamous cell neoplasia: Initial
multicenter international experience with a novel portable
cryoballoon ablation system (with video). Gastrointest Endosc.
87:574–581. 2018. View Article : Google Scholar
|
|
4
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li Y, Wu X, Li L, Liu Y, Xu C, Su D and
Liu Z: The E3 ligase HECTD3 promotes esophageal squamous cell
carcinoma (ESCC) growth and cell survival through targeting and
inhibiting caspase-9 activation. Cancer Lett. 404:44–52. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kjaer DW, Larsson H, Svendsen LB and
Jensen LS: Changes in treatment and outcome of oesophageal cancer
in Denmark between 2004 and 2013. Br J Surg. 104:1338–1345. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Martin-Richard M, Díaz Beveridge R,
Arrazubi V, Alsina M, Galan Guzmán M, Custodio AB, Gómez C, Muñoz
FL, Pazo R and Rivera F: SEOM Clinical Guideline for the diagnosis
and treatment of esophageal cancer (2016). Clin Transl Oncol.
18:1179–1186. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sohda M and Kuwano H: Current status and
future prospects for esophageal cancer treatment. Ann Thorac
Cardiovasc Surg. 23:1–11. 2017. View Article : Google Scholar :
|
|
9
|
Arnold M, Laversanne M, Brown LM, Devesa
SS and Bray F: Predicting the future burden of esophageal cancer by
histological subtype: International trends in incidence up to 2030.
Am J Gastroenterol. 112:1247–1255. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Palumbo Júnior A, Da Costa NM, Esposito F,
Fusco A and Pinto LF: High Mobility Group A proteins in esophageal
carcinomas. Cell Cycle. 15:2410–2413. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pan F, Mao H, Bu F, Tong X, Li J, Zhang S,
Liu X, Wang L, Wu L, Chen R, et al: Sp1-mediated transcriptional
activation of miR-205 promotes radioresistance in esophageal
squamous cell carcinoma. Oncotarget. 8:5735–5752. 2017.
|
|
12
|
Sugihara H, Ishimoto T, Miyake K, Izumi D,
Baba Y, Yoshida N, Watanabe M and Baba H: Noncoding RNA expression
aberration is associated with cancer progression and is a potential
biomarker in esophageal aquamous cell carcinoma. Int J Mol Sci.
16:27824–27834. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Goense L, van Rossum PS, Kandioler D,
Ruurda JP, Goh KL, Luyer MD, Krasna MJ and van Hillegersberg R:
Stage-directed individualized therapy in esophageal cancer. Ann N Y
Acad Sci. 1381:50–65. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cleary JM, Mamon HJ, Szymonifka J, Bueno
R, Choi N, Donahue DM, Fidias PM, Gaissert HA, Jaklitsch MT, Kulke
MH, et al: Neoadjuvant irinotecan, cisplatin, and concurrent
radiation therapy with celecoxib for patients with locally advanced
esophageal cancer. BMC Cancer. 16:4682016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Phatak P, Byrnes KA, Mansour D, Liu L, Cao
S, Li R, Rao JN, Turner DJ, Wang JY and Donahue JM: Overexpression
of miR-214-3p in esophageal squamous cancer cells enhances
sensitivity to cisplatin by targeting survivin directly and
indirectly through CUG-BP1. Oncogene. 35:2087–2097. 2016.
View Article : Google Scholar :
|
|
16
|
Wu Y and Jiang M: The revolution of lung
cancer treatment: from vaccines, to immune checkpoint inhibitors,
to chimeric antigen receptor T therapy. Biotarget. 1:72017.
View Article : Google Scholar
|
|
17
|
Liu T, Li R, Zhao H, Deng J, Long Y, Shuai
MT, Li Q, Gu H, Chen YQ and Leng AM: eIF4E promotes tumorigenesis
and modulates chemosensitivity to cisplatin in esophageal squamous
cell carcinoma. Oncotarget. 7:66851–66864. 2016.PubMed/NCBI
|
|
18
|
Komatsu S, Ichikawa D, Kawaguchi T,
Miyamae M, Okajima W, Ohashi T, Imamura T, Kiuchi J, Konishi H,
Shiozaki A, et al: Circulating miR-21 as an independent predictive
biomarker for chemoresistance in esophageal squamous cell
carcinoma. Am J Cancer Res. 6:1511–1523. 2016.PubMed/NCBI
|
|
19
|
Sumner ET, Chawla AT, Cororaton AD,
Koblinski JE, Kovi RC, Love IM, Szomju BB, Korwar S, Ellis KC and
Grossman SR: Transforming activity and therapeutic targeting of
C-terminal-binding protein 2 in Apc-mutated neoplasia. Oncogene.
36:4810–4816. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dai F, Xuan Y, Jin JJ, Yu S, Long ZW, Cai
H, Liu XW, Zhou Y, Wang YN, Chen Z, et al: CtBP2 overexpression
promotes tumor cell proliferation and invasion in gastric cancer
and is associated with poor prognosis. Oncotarget. 8:28736–28749.
2017.PubMed/NCBI
|
|
21
|
Riku M, Inaguma S, Ito H, Tsunoda T, Ikeda
H and Kasai K: Down-regulation of the zinc-finger homeobox protein
TSHZ2 releases GLI1 from the nuclear repressor complex to restore
its transcriptional activity during mammary tumorigenesis.
Oncotarget. 7:5690–5701. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zheng X, Song T, Dou C, Jia Y and Liu Q:
CtBP2 is an independent prognostic marker that promotes GLI1
induced epithelial-mesenchymal transition in hepatocellular
carcinoma. Oncotarget. 6:3752–3769. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang C, Li S, Qiao B, Yang K, Liu R, Ma
B, Liu Y, Zhang Z and Xu Y: CtBP2 overexpression is associated with
tumorigenesis and poor clinical outcome of prostate cancer. Arch
Med Sci. 11:1318–1323. 2015. View Article : Google Scholar
|
|
24
|
Yang X, Sun Y, Li H, Shao Y, Zhao D, Yu W
and Fu J: C-terminal binding protein-2 promotes cell proliferation
and migration in breast cancer via suppression of p16INK4A.
Oncotarget. 8:26154–26168. 2017.PubMed/NCBI
|
|
25
|
Frietze S, O'Geen H, Littlepage LE, Simion
C, Sweeney CA, Farnham PJ and Krig SR: Global analysis of ZNF217
chromatin occupancy in the breast cancer cell genome reveals an
association with ERalpha. BMC Genomics. 15:5202014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
May T, Yang J, Shoni M, Liu S, He H, Gali
R, Ng SK, Crum C, Berkowitz RS and Ng SW: BRCA1 expression is
epigenetically repressed in sporadic ovarian cancer cells by
overexpression of C-terminal binding protein 2. Neoplasia.
15:600–608. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guan C, Shi H, Wang H, Zhang J, Ni W, Chen
B, Hou S, Yang X, Shen A and Ni R: CtBP2 contributes to malignant
development of human esophageal squamous cell carcinoma by
regulation of p16INK4A. J Cell Biochem. 114:1343–1354. 2013.
View Article : Google Scholar
|
|
28
|
Zhang J, Zhu J, Yang L, Guan C, Ni R, Wang
Y, Ji L and Tian Y: Interaction with CCNH/CDK7 facilitates CtBP2
promoting esophageal squamous cell carcinoma (ESCC) metastasis via
upregulating epithelial-mesenchymal transition (EMT) progression.
Tumour Biol. 36:6701–6714. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Birts CN, Harding R, Soosaipillai G,
Halder T, Azim-Araghi A, Darley M, Cutress RI, Bateman AC and
Blaydes JP: Expression of CtBP family protein isoforms in breast
cancer and their role in chemoresistance. Biol Cell. 103:1–19.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
31
|
Ansari S, Chen C, Hasani-Sadrabadi MM, Yu
B, Zadeh HH, Wu BM and Moshaverinia A: Hydrogel elasticity and
microarchitecture regulate dental-derived mesenchymal stem
cell-host immune system cross-talk. Acta Biomater. 60:181–189.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mihaly SR, Sakamachi Y, Ninomiya-Tsuji J
and Morioka S: Noncanocial cell death program independent of
caspase activation cascade and necroptotic modules is elicited by
loss of TGFβ-activated kinase 1. Sci Rep. 7:29182017. View Article : Google Scholar
|
|
33
|
Luna C, Mendoza N, Casao A, Pérez-Pé R,
Cebrián-Pérez JA and Muiño-Blanco T: c-Jun N-terminal kinase and
p38 mitogen-activated protein kinase pathways link capacitation
with apoptosis and seminal plasma proteins protect sperm by
interfering with both routes. Biol Reprod. 96:800–815. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Whiteside TL: Stimulatory role of exosomes
in the context of therapeutic anti-cancer vaccines. Biotarget.
1:52017. View Article : Google Scholar
|
|
35
|
Kwon D, Yun JY, Keam B, Kim YT and Jeon
YK: Prognostic implications ofFGFR1andMYCstatus in esophageal
squamous cell carcinoma. World J Gastroenterol. 22:9803–9812. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen P, Zhang JY, Sha BB, Ma YE, Hu T, Ma
YC, Sun H, Shi JX, Dong ZM and Li P: Luteolin inhibits cell
proliferation and induces cell apoptosis via down-regulation of
mitochondrial membrane potential in esophageal carcinoma cells EC1
and KYSE450. Oncotarget. 8:27471–27480. 2017.PubMed/NCBI
|
|
37
|
Zhang HF, Wu C, Alshareef A, Gupta N, Zhao
Q, Xu XE, Jiao JW, Li EM, Xu LY and Lai R: The PI3K/AKT/c-MYC axis
promotes the acquisition of cancer stem-like features in esophageal
squamous cell carcinoma. Stem Cells. 34:2040–2051. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Konishi H, Fujiwara H, Shiozaki A, Shoda
K, Kosuga T, Kubota T, Okamoto K and Otsuji E: Effects of
neoadjuvant 5-fluorouracil and cisplatin therapy in patients with
clinical stage II/III esophageal squamous cell carcinoma.
Anticancer Res. 38:1017–1023. 2018.PubMed/NCBI
|
|
39
|
Liu B, Wang C, Chen P, Cheng B and Cheng
Y: RACKI induces chemotherapy resistance in esophageal carcinoma by
upregulating the PI3K/AKT pathway and Bcl-2 expression. Onco
Targets Ther. 11:211–220. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Veena MS, Wilken R, Zheng JY, Gholkar A,
Venkatesan N, Vira D, Ahmed S, Basak SK, Dalgard CL, Ravichandran
S, et al: p16 protein and gigaxonin are associated with the
ubiquitination of NFκB in cisplatin-induced senescence of cancer
cells. J Biol Chem. 289:34921–34937. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Geiger JL, Lazim AF, Walsh FJ, Foote RL,
Moore EJ, Okuno SH, Olsen KD, Kasperbauer JL, Price DL, Garces YI,
et al: Adjuvant chemoradiation therapy with high-dose versus weekly
cisplatin for resected, locally-advanced HPV/p16-positive and
negative head and neck squamous cell carcinoma. Oral Oncol.
50:311–318. 2014. View Article : Google Scholar : PubMed/NCBI
|
